For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Retatrutide
Illustration for Retatrutide

THE PEPSRADAR ENCYCLOPEDIA

Retatrutide

GLP-1, GIP, and glucagon receptor research

Investigational · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Corrected October 11, 2026: We removed upcoming-trial records that turned out not to be real studies (fake ClinicalTrials.gov registrations). Corrections log

Retatrutide · KEY FACTS

Content updated · how dates work

Saved peptides

Compare: Tirzepatide vs Retatrutide

What is Retatrutide?

Retatrutide is a triple-receptor agonist investigated for obesity and related metabolic conditions. Its trial identity differs from unverified coded seller listings.

Video overview · 2:49

Retatrutide: What the Trials Actually Show (and Why "Research" Vials Aren't the Same)

How the triple-hormone drug is thought to work, what the phase 2 and phase 3 trials found, the side effects, the trials still under way, its legal status, and why vials sold online are not the drug tested in those trials.

Narrated with an AI voice from this profile's sources; education only, no dosing.

Read the transcript

Retatrutide is an experimental drug from Eli Lilly that acts on three hormone targets at once. In large trials, people lost a lot of weight on average. But it is not approved, and the vials sold online as research chemicals are not the drug tested in those trials. Here is what is actually known.

Retatrutide is a single molecule that switches on receptors for three hormones. Two of them, GLP-1 and GIP, are gut hormones involved in appetite and blood sugar. The third, glucagon, affects how the body uses energy. Researchers are testing whether hitting all three together works better than one or two, and what it means over the long term.

Unlike most peptides sold online, retatrutide has real human data. In TRIUMPH-1, a phase 3 trial of more than two thousand adults without diabetes, average weight loss over eighty weeks ranged from about eighteen to twenty-five percent across the study groups, compared with about four percent on placebo. In people with type 2 diabetes, weight loss was smaller, about twelve to nineteen percent.

The most common side effects were digestive: nausea, diarrhea, vomiting and constipation. Trials also saw faster heart rates, and in people with diabetes, low blood pressure was more common than on placebo. Some people stopped treatment because of side effects. Eighty weeks is not long enough to know the long-term risks.

More answers are coming. A trial of about ten thousand adults is testing whether retatrutide affects heart attacks, strokes and kidney disease, with results expected around 2029. Another compares it directly with semaglutide in people with type 2 diabetes.

Retatrutide is not FDA approved. The FDA says it cannot legally be used by compounding pharmacies, and it has sent warning letters to companies selling it, including so-called research peptide sellers. And as an unapproved substance, it is likely covered by the anti-doping ban on unapproved drugs.

Is research-labeled retatrutide the same as the drug in these trials? PepsRadar's claim check says no. Vials sold online have none of the manufacturing oversight, and published tests of online GLP-1 products have found mislabeled and low-purity products. Seller codes like GLP-3 or R are shorthand, not verified identities. And it is not approved yet: phase 3 trials are still under way.

The bottom line: retatrutide has impressive results in large human trials, common digestive side effects, unknown long-term risks, and no approval yet. For every study and source, see the retatrutide profile on PepsRadar dot com.

Biological role or research focus

GLP-1, GIP, and glucagon receptor research.

“R”, “Reta”, and “GLP-3” are candidate seller shorthand, not verified product identities.

Role reference: Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. ↗

Names you may encounter

LY3437943 · GLP-3 · reta

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
GLP-1 / GIP / glucagon receptor agonist
Main research area
Investigational metabolic therapy
Evidence featured
Human phase 2 randomized trial
Source check
October 4, 2026

Source: Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. ↗

Quick answers

Is Retatrutide FDA approved?
No. No FDA-approved drug contains Retatrutide. Source ↗
Is Retatrutide safe?
Investigational triple-hormone drug, not FDA-approved. Large trials report frequent digestive side effects, heart-rate increases and some low blood pressure; long-term risks are unknown. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
Is Retatrutide banned in sport?
Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
Has the FDA taken action over Retatrutide?
Yes. Our records list 3 FDA actions naming it, most recently on October 1, 2026: FDA states retatrutide cannot be used in compounding and that it has warned telehealth firms, API distributors and outsourcing facilities over retatrutide (page updated October 1, 2026). Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

5 Human research
StudyTypePopulation / model
Triple-receptor obesity trial (2023)Human phase 2 randomized trial338 adults with obesity, or overweight with a weight-related condition.
Phase 2 trial in type 2 diabetes (2023)Human randomized trial281 adults with type 2 diabetes randomized; 275 included in efficacy analyses.
TRIUMPH-1 phase 3 obesity trial (2026)Human phase 3 randomized trial2,339 adults with obesity and without diabetes, including 574 with knee osteoarthritis and 243 with obstructive sleep apnea.
TRIUMPH-4 phase 3 trial in knee osteoarthritis (2026)Human phase 3 randomized trial445 adults without diabetes who had painful knee osteoarthritis and a BMI of 27 or higher. The same paper reports the 574 TRIUMPH-1 participants with knee osteoarthritis.
TRIUMPH-2 phase 3 trial in type 2 diabetes (2026)Human phase 3 randomized trial1,152 adults with overweight or obesity (BMI 27 or higher) and type 2 diabetes at 92 centers in eight countries; mean age 55.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human phase 2 randomized trial · 2023

Triple-receptor obesity trial

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.

Population / model
338 adults with obesity, or overweight with a weight-related condition.
Study design
Forty-eight-week randomized, blinded, placebo-controlled study; primary endpoint at 24 weeks.
Main finding
At 48 weeks, average weight reduction reached 24.2% in the highest studied group versus 2.1% with placebo. Gastrointestinal events and dose-related heart-rate increases were reported.
Limits & context
This early efficacy trial does not establish long-term outcomes or verify commercial “R” products. Study doses describe the trial, not instructions for using research chemicals.

Source: Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. ↗

Human randomized trial · 2023

Phase 2 trial in type 2 diabetes

What did the separate diabetes trial add to the obesity findings?

Population / model
281 adults with type 2 diabetes randomized; 275 included in efficacy analyses.
Study design
Double-blind phase 2 study with placebo and dulaglutide comparators. Primary endpoint: HbA1c change at 24 weeks; follow-up continued to 36 weeks.
Main finding
At 24 weeks, mean HbA1c reductions ranged from 0.43 to 2.02 percentage points across retatrutide groups, versus 0.01 with placebo and 1.41 with dulaglutide. All but the lowest retatrutide group outperformed placebo on that endpoint. Gastrointestinal adverse events were reported.
How to read it
This study supports a glucose-control research question in diabetes; it is separate from the 338-participant obesity study.
Limits & context
Phase 2 size and duration limit conclusions about uncommon harms and long-term outcomes. Not every retatrutide group outperformed the active comparator. Trial findings do not authenticate coded “R” seller listings. Funded by Eli Lilly.

Source: Rosenstock et al. · The Lancet · 2023 ↗

Human phase 3 randomized trial · 2026

TRIUMPH-1 phase 3 obesity trial

Do the phase 2 weight results hold up in a large, longer trial, and what happens to knee pain and sleep apnea?

Population / model
2,339 adults with obesity and without diabetes, including 574 with knee osteoarthritis and 243 with obstructive sleep apnea.
Study design
Randomized, double-blind, placebo-controlled phase 3 trial of once-weekly retatrutide at three dose levels for 80 weeks. Primary outcomes: percent weight change, knee-pain score in the osteoarthritis subgroup, and breathing interruptions per hour in the sleep apnea subgroup.
Main finding
Average weight change was -17.6%, -23.7% and -25.0% across the three retatrutide groups versus -3.9% with placebo. Knee pain and sleep apnea events improved more than with placebo in their subgroups. Gastrointestinal events were the most common adverse events.
How to read it
TRIUMPH-1 confirms the scale of phase 2 weight loss in a population about seven times larger, followed for 80 weeks.
Limits & context
Funded by Eli Lilly. Eighty weeks cannot show long-term safety, weight maintenance after stopping, or effects on heart attacks and strokes. Retatrutide remained investigational when checked, and trial results do not verify any seller listing.

Source: TRIUMPH-1 · N Engl J Med · 2026 ↗

Human phase 3 randomized trial · 2026

TRIUMPH-4 phase 3 trial in knee osteoarthritis

Does retatrutide reduce knee pain, as well as weight, in adults with obesity and painful knee osteoarthritis?

Population / model
445 adults without diabetes who had painful knee osteoarthritis and a BMI of 27 or higher. The same paper reports the 574 TRIUMPH-1 participants with knee osteoarthritis.
Study design
Randomized, double-blind, placebo-controlled phase 3 trial of once-weekly retatrutide at two dose levels for 68 weeks. Primary outcomes: change in WOMAC knee-pain score (0 to 10, higher is worse) and percent weight change.
Main finding
WOMAC pain fell by 3.96 and 3.74 points on the two retatrutide doses versus 2.12 points on placebo. Average weight change was -20.0% and -23.7% versus -4.6% with placebo. The TRIUMPH-1 knee group pointed the same way at 80 weeks. In both trials, serious adverse events were more common with retatrutide than with placebo, and gastrointestinal events were the most common adverse events.
How to read it
In people whose knee pain comes with obesity, retatrutide reduced pain by about 1.4 to 1.8 points more than placebo on a 10-point scale, alongside large weight loss.
Limits & context
Funded by Eli Lilly. The placebo groups also improved, the trial cannot separate the effect of weight loss from any direct effect on the joint, and 68 weeks cannot show long-term safety. Retatrutide remained investigational and not FDA-approved when checked, and trial results do not verify any seller listing.

Source: TRIUMPH-4 · N Engl J Med · 2026 ↗

Human phase 3 randomized trial · 2026

TRIUMPH-2 phase 3 trial in type 2 diabetes

How much weight do adults with type 2 diabetes lose on retatrutide over 80 weeks?

Population / model
1,152 adults with overweight or obesity (BMI 27 or higher) and type 2 diabetes at 92 centers in eight countries; mean age 55.
Study design
Randomized, double-blind, placebo-controlled phase 3 trial of once-weekly retatrutide at three dose levels for 80 weeks. Primary outcome: percent weight change.
Main finding
Average weight change was -11.9%, -16.8% and -18.8% across the three retatrutide groups versus -5.1% with placebo, and 84% of participants completed the study drug. Gastrointestinal events were the most frequent adverse events.
How to read it
Weight loss was smaller than in people without diabetes, a pattern also seen with other incretin medicines.
Limits & context
Funded by Eli Lilly. Long-term safety and cardiovascular outcomes need separate trials, and results describe the manufacturer’s study drug only.

Source: TRIUMPH-2 · The Lancet · 2026 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

34 registered studies name Retatrutide as an intervention; 10 are recruiting or under way, 0 have not started recruiting yet, 22 completed and 2 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603 · Eli Lilly and Company
Active, not recruitingPhase 32024-03-15320
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
NCT07232719 · Eli Lilly and Company
Active, not recruitingPhase 32025-11-17250
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
NCT05936151 · Eli Lilly and Company
CompletedPhase 22023-07-20146
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028 · Eli Lilly and Company
RecruitingPhase 32025-10-154500
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390 · Eli Lilly and Company
Active, not recruitingPhase 32024-04-3010000
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
NCT06982859 · Eli Lilly and Company
Active, not recruitingPhase 12025-06-0295
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT06260722 · Eli Lilly and Company
Active, not recruitingPhase 32024-02-211250
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
NCT07035093 · Eli Lilly and Company
Active, not recruitingPhase 32025-05-29586

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 34 listed studies.

Related records in our PubMed snapshot

Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis. ↗
Rapid communications in mass spectrometry : RCM · Issue date 2026 Dec 15 · Not appraised

The First Triple Agonist for Antiobesity: Retatrutide. ↗
Cardiology in review · Issue date 2026 Nov-Dec 01 · Not appraised

Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats. ↗
Behavioural brain research · Issue date 2026 Oct 2 · Not appraised

Retatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest. ↗
BMJ (Clinical research ed.) · Issue date 2026 Oct 1 · Not appraised

Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. ↗
The New England journal of medicine · Issue date 2026 Sep 29 · Not appraised

Search additional PubMed records ↗

Risks & interactions

Investigational triple-hormone drug, not FDA-approved. Large trials report frequent digestive side effects, heart-rate increases and some low blood pressure; long-term risks are unknown.

Human safety data: Trials only

Phase 2 trials and 80-week phase 3 trials (TRIUMPH-1 and -2) report mainly gastrointestinal side effects. Deaths in TRIUMPH-2 were judged unrelated by investigators. Two 80-week phase 3 sleep apnea trials (TRIUMPH-1-OSA and TRIUMPH-2-OSA, 691 adults, N Engl J Med 2026) reported fewer breathing interruptions per hour than placebo alongside about 18-22% weight loss, so the benefit cannot be separated from the weight lost. In the 24-week phase 2b TRANSCEND-CKD trial (146 adults with chronic kidney disease and excess weight, presented at ASN Kidney Week 2026, not yet published), measured kidney filtration, the main endpoint, did not change versus placebo; among people with raised urine albumin, albumin fell about 54% versus 9% on placebo, and pulse rose about 9 beats per minute. Heart, cancer and long-term outcomes are still being studied.

Take extra care with: Heart or blood pressure problems

Warnings for approved drugs in the same class (semaglutide, tirzepatide, liraglutide, dulaglutide), which may apply here too: Diabetes or blood-sugar medicinesCancer, now or in the pastPregnancy or breastfeedingKidney problemsBlood thinners or bleeding problems

It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Interactions

  • Anesthesia or sedation: GLP-1-based medicines slow stomach emptying, and reviews flag retained stomach contents as a class concern
  • Blood-pressure-lowering medicines: low blood pressure was more frequent with retatrutide than placebo in a phase 3 trial

Serious risks

  • Low blood pressure (hypotension), more frequent than with placebo in TRIUMPH-2
  • Stopping treatment because of side effects was more common in some retatrutide groups than with placebo
  • Pancreas and gallbladder problems are discussed as safety concerns for GLP-1-based medicines as a class
  • FDA says retatrutide sold 'for research purposes' is unapproved and of unknown quality

Side effects reported in studies

  • nausea
  • diarrhea
  • vomiting
  • constipation
  • increased heart rate
  • abnormal skin sensations (dysesthesia)

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Retatrutide for obesity: phase 2 trial (N Engl J Med, 2023) ↗ · TRIUMPH-1 phase 3 trial (N Engl J Med, 2026) ↗ · TRIUMPH-2 phase 3 trial (Lancet, 2026) ↗ · Retatrutide for obstructive sleep apnea: TRIUMPH-1-OSA and TRIUMPH-2-OSA (N Engl J Med, 2026) ↗ · TRANSCEND-CKD phase 2b results, ASN Kidney Week 2026 (HCPLive conference report) ↗ · Efficacy and safety of GLP-1 medicines (review) ↗ · FDA: Concerns with unapproved GLP-1 drugs ↗

Safety evidence & remaining uncertainty

Gastrointestinal effects and heart-rate changes appeared in the phase 2 trial. That study cannot establish every long-term risk or the identity and safety of a vendor vial.

Source: Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on any 503A category list. FDA states retatrutide cannot be used in compounding under federal law (not a component of an approved drug, no USP/NF monograph, not on the 503A bulks list). source
World Anti-Doping Agency (2026)
Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source

FDA actions

  • FDA states retatrutide cannot be used in compounding and that it has warned telehealth firms, API distributors and outsourcing facilities over retatrutide (page updated October 1, 2026). (2026-10-01) source
  • FDA warning letter (GLP-1 Solution) stating compounded retatrutide does not qualify for 503A exemptions: no USP/NF monograph, not a component of an approved drug, not on the 503A bulks list. (2025-09-09) source
  • FDA warning letter to a "research peptide" seller (Peptide Partners) naming "GLP-3" (retatrutide) and other peptides as unapproved new drugs despite research-use-only labeling. (2026-08-24) source

Other notes

  • Retatrutide (via importer description) is one of the GLP-1 active ingredients covered by FDA Import Alert 66-80 (detention without physical examination of GLP-1 bulk drug substances from non-green-listed makers; revised September 2026). source
  • October 14, 2026: a group of U.S. senators led by Sen. Jim Banks wrote to the acting FDA commissioner calling "for research use only" labeling "a dangerous loophole". Citing America's Poison Centers, the letter says poisonings tied to illicit retatrutide rose 265% in January-April 2026 versus September-December 2025, and that some products sold as retatrutide contained none. It asks FDA to work with Customs and Border Protection and law enforcement and requests a briefing. A letter is a request; it does not change the law. source
  • October 2026: CBS News bought what was sold as retatrutide from an online clinic, a gym and a Brooklyn bodega and had it lab-tested. The bodega vial contained a chemical filler (phenylacetic acid) and bacteria. CBS also reported two recent deaths reported to FDA that may be linked to black-market retatrutide; FDA has not verified them. source
  • TRM Labs (October 6, 2026): crypto payments to Chinese vendors that list both peptides and fentanyl precursors rose 32%, from 28.2 million to 37.3 million US dollars between 2023 and 2025; about 57% of identifiable payments came from the United States. TRM cannot separate peptide payments from fentanyl-precursor payments. source
  • Canada, November 6, 2026: Health Canada warned consumers not to buy or inject unauthorized peptides sold online after lab tests of vials seized from a Chinese supplier found bacteria, including Acinetobacter seifertii, Acinetobacter nosocomialis and Cutibacterium acnes. It seized over 11,400 vials from the supplier and two Canadian online retailers, whose websites are no longer active. Unauthorized products sold as retatrutide were among the example products listed. Authorized drugs for sale in Canada carry an 8-digit Drug Identification Number (DIN) on the label. source
  • Australia, November 5, 2026: TGA laboratory testing of one brand's unapproved peptide products, identified while assisting NSW Police (Strike Force Antree), found no detectable TB-500 in three products labelled as containing it, and "Retatrutide 10 mg" vials with less retatrutide than stated, with significant variation between samples. The TGA says consumers cannot rely on the labels to know what they are taking or how much. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & status

This profile presents investigational obesity evidence. FDA’s unapproved-GLP-1 information states that retatrutide is not a component of an FDA-approved drug. Study reports should be dated and distinguished from approval announcements.

Source: FDA · Unapproved GLP-1 products ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

PepsRadar does not list, compare or link GLP-1-class products, even though some sellers we track elsewhere on the site also sell them. This drug is still investigational and is not approved for sale. The FDA warns that versions sold online as "research" products are unapproved and of unknown quality (FDA).

Mechanism & research rationale

It engages GLP-1, GIP, and glucagon receptors in one molecule. Clinical trials test the combined effects rather than assuming that adding receptor targets guarantees better outcomes.

Source: Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. ↗

Molecular structure

Retatrutide: sequence & modification map. A sequence and modification map based on the NIH GSRS definition. Aib replaces residues 2 and 20; residue 13 is alpha-methyl-leucine; Lys17 carries a lipid side chain. This is not a bond-by-bond drawing or 3D fold.⤢ Enlarge 2D
Sequence & modification mapA sequence and modification map based on the NIH GSRS definition. Aib replaces residues 2 and 20; residue 13 is alpha-methyl-leucine; Lys17 carries a lipid side chain. This is not a bond-by-bond drawing or 3D fold.NIH GSRS · NOP2Y096GV ↗

Questions worth asking

  • Which exact product is being discussed?
  • Is a podcast describing a study, an approved indication, or a personal experience?
  • “R”, “Reta”, and “GLP-3” are candidate seller shorthand, not verified product identities.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Video & podcast discussions: members library

Frequently asked questions

Can “R,” “Reta,” or “GLP-3” confirm what a vial contains?

No. They are search clues, not verified chemical identities.

Source: FDA · Unapproved GLP-1 products ↗

Does a phase 2 result establish a safe commercial product?

No. Trial material, controlled monitoring, and commercial product quality are separate issues.

Source: Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. ↗

What does the TRIUMPH-2 phase 3 trial in type 2 diabetes study show, and what does it not?

Weight loss was smaller than in people without diabetes, a pattern also seen with other incretin medicines. Funded by Eli Lilly. Long-term safety and cardiovascular outcomes need separate trials, and results describe the manufacturer’s study drug only.

Source: TRIUMPH-2 · The Lancet · 2026 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

PUT THE EVIDENCE IN CONTEXT

Research guides

RESEARCH FIELD GUIDE

GLP-1s and keto: a real-food playbook for losing fat, not muscle

A GLP-1 medicine turns down your appetite. What you eat with that smaller appetite decides how much of the weight you lose is fat and how much is muscle. Lived experience and the published research on cutting carbs, ketones, electrolytes, kidney stones, muscle, fasting, real food and sleep, including where the evidence is thin.

Read the guide →

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Retatrutide

Download illustration ↓Source record ↗
Retatrutide sequence & modification map

A sequence and modification map based on the NIH GSRS definition. Aib replaces residues 2 and 20; residue 13 is alpha-methyl-leucine; Lys17 carries a lipid side chain. This is not a bond-by-bond drawing or 3D fold.